Current Research Studies

Cancer – ANBL1821: Phase 2 Randomized Study of Irinotecan/Temozoloide/Dinutuximab with or without Eflornithine in Children with Relapsed, Refractory or Progressive Neuroblastoma

Condition or Therapy:

Neuroblastoma, Ganglioneuroblastoma


Cancer and Blood Disorders
Study Number: ANBL1821

What is the goal of this study?

The goal of this study is to determine if the addition of eflornithine (DFMO) in combination with dinutuximab, irinotecan, and temozolomide results in an improved response in patients with relapsed or refractory neuroblastoma.

Who can join the study?

This study might be a good fit for children who:

  • Are 1 year or older and,
  • Have had a refractory, relapsed or progressive neuroblastoma or ganglioneuroblastoma.

What will happen if my child takes part in this study?

You can read more about this study at

Who can I contact for more information?

To learn more, call (206) 987-2106 or send us an email.

Study Location(s):

Seattle Children's Main Hospital Campus

Principal Investigator:

Dr. Navin Robert Pinto